H.C. Wainwright analyst Edward White raised the firm’s price target on Dynavax to $29 from $28 and keeps a Buy rating on the shares. The analyst cites higher revenue estimates post the Q4 report for the target bump. Dynavax expects to be cash flow positive in 2024 and management intends to use the company’s cash position to look for opportunities to diversify its pipeline, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DVAX:
- Dynavax Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Financial Guidance
- Qualcomm downgraded, Cigna upgraded: Wall Street’s top analyst calls
- Dynavax initiated with a Neutral at Goldman Sachs
- Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Highlights
- Dynavax sees FY23 HEPLISAV-B vaccine net product revenue about $213M
